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Abstract
Background Obesity and chronic low-grade inﬂammation have both been implicated in the onset of physical fatigue.
However, few studies have investigated the independence of these associations in older community-dwelling populations.
We therefore aimed to investigate the associations of body mass index (BMI) and inﬂammatory markers at age 60–64 with
perceived physical fatigability at age 68 and to assess whether any such associations were independent of each other and
potential confounding factors. A secondary aim was to investigate whether any association with BMI extended back into
earlier adulthood.
Methods Participants of the MRC National Survey of Health and Development (N= 1580) had BMI and levels of
interleukin-6 (IL-6) and C-reactive protein (CRP) measured during clinical assessments at age 60–64. These were related to
self-perceived physical fatigability assessed at age 68 using the Pittsburgh Fatigability Scale (PFS) (total score:0 (no physical
fatigue)–50 (extreme physical fatigue)).
Resuts Women had higher mean PFS scores than men (mean (SD): 16.0 (9.1) vs 13.2 (8.9), p < 0.01). In sex-adjusted
models, BMI, CRP and IL-6 were each associated with PFS scores. When all three factors were included in the same model,
BMI and IL-6 remained associated with PFS scores whereas CRP did not. After adjustment for a range of potential
confounders, associations of BMI and IL-6 with PFS scores were still evident; fully adjusted differences in mean PFS score
= 3.41 (95% CI: 0.59, 6.24) and 1.65 (0.46, 2.84) for underweight and obese participants when compared with normal
weight and, 2.78 (1.65, 3.91) when comparing those with an IL-6 of 2.51–8.49 pg/mL with levels <1.50.
Conclusions BMI and inﬂammation may both be suitable targets for intervention to reduce the burden of physical
fatigability in later life. Further, interventions that target both obesity and elevated levels of IL-6 are likely to be more
effective than those focusing on only one.
Introduction
Physical fatigue is a commonly reported symptom often
present even in the absence of clinically manifest disease
[1–3]. Levels of fatigue in the general population have been
shown to increase with age across adulthood [4–6]. These
age-related changes are proposed as key precipitants of
declines in activity participation and physical function later
in life [1–3, 7]. The importance of fatigue is further high-
lighted by evidence of longitudinal associations with
increased risk of a range of adverse health outcomes
including disability and premature mortality [1, 8–12] and
by its inclusion, on the basis of such evidence, as a
component of geriatric syndromes including frailty [13].
Identifying modiﬁable risk factors associated with physical
fatigue in later life could present new opportunities to
reduce its burden in the ageing population.
Chronic low-grade inﬂammation, a potentially important
driver of a wide range of ageing processes [14–16], may be
implicated in the onset of physical fatigue [1–3, 17]. Based
primarily on ﬁndings from animal models and studies of
disease-speciﬁc patient groups, a number of plausible
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biological mechanisms have been proposed which could
explain a link between inﬂammation and fatigue [18, 19].
Although generally consistent, epidemiological evidence
from general population-based samples is relatively
limited as the majority of studies have been small (n < 200)
and cross-sectional [20–24]. While longitudinal analyses
have been undertaken to establish temporality in two
larger studies [25, 26], only one of these includes older
adults [26].
Adiposity, usually indicated by higher body mass index
(BMI), has also been suggested as a potential risk factor for
physical fatigue. While this association has been investi-
gated in a number of studies [21–24, 27–34], ﬁndings are
not fully consistent. Where evidence of association has been
found, this is often non-linear with those groups who are
underweight and obese reporting greater prevalence of
fatigue than those of normal weight [27, 30, 32, 33]. Many
studies of this association are limited by cross-sectional
designs [28–32] or relatively short follow-up [27]. In
addition, although overweight and obesity across life have
been related to low-grade inﬂammation [35–38], few
studies have investigated whether the association
between BMI and physical fatigue is mediated by, or
independent of, inﬂammation. Establishing this would
provide further insight into underlying aetiology and help
determine whether one or both sets of factors are mean-
ingful targets for intervention to prevent physical fatigue in
older adults.
An additional limitation of existing studies of physical
fatigue and, a source of heterogeneity between studies, is
the use of a range of different self-reported measures of
fatigue none of which account for situation. This is parti-
cularly problematic in older populations where adaptations,
such as avoiding speciﬁc physical tasks or undertaking them
more slowly (i.e. self-pacing), may be made to avoid fatigue
[39]. If differential levels of adaptation have been taken in
different risk proﬁle groups, as suggested by recent ﬁndings
on obesity history and daily patterns of activity [40], this
could introduce bias and attenuate results towards the null.
Further research, using whole-body measures of physical
fatigability, which assess perceptions of fatigue in the
context of speciﬁc standard activities of a ﬁxed intensity
and duration [3, 39], is thus required.
Using data from a nationally representative birth cohort,
the MRC National Survey of Health and Development
(NSHD), our primary aim was to investigate the associa-
tions of BMI and inﬂammatory markers at age 60–64 with a
validated measure of perceived physical fatigability which
takes account of situation at age 68 and to assess whether
any such associations were independent of each other and
potential confounding factors. A secondary aim was to
investigate whether any effect of BMI extended back into
earlier adulthood.
Subjects and methods
The NSHD is a socially stratiﬁed sample of 5362 births that
occurred during one week of March 1946 in mainland
Britain, with regular follow-up across life [41–43]. The 24th
data collection was conducted between 2014 and 2015
when study members were asked to complete a postal
questionnaire at age 68 and then invited to receive a nurse
home visit at age 69 [43]. Of the 2816 study members in the
target sample living in England, Scotland and Wales, 2370
(84%) completed the postal questionnaire. In addition, a
postal questionnaire was sent to 126 study members living
abroad who remain in contact with the study of whom 83
(66%) completed this. No attempt was made to contact the
remaining 2420 study members: 957 (18%) had died, 620
(12%) had previously withdrawn from the study, 448 (8%)
had emigrated and were no longer in contact with the
study, and 395 (7%) had been untraceable for more than
5 years [43].
Ethical approval for the 2014–2015 assessment was
obtained from the Queen Square Research Ethics
Committee (14/LO/1073) and the Scotland A Research
Ethics Committee (14/SS/1009). Study members provided
written informed consent.
Ascertainment of perceived physical fatigability
Physical fatigability was assessed in the postal
questionnaire at age 68 using the Pittsburgh Fatigability
Scale (PFS) [39]. Study members were asked to indicate the
level of physical fatigue they expected or imagined they
would feel after completing ten activities on a scale from 0
(no fatigue) to 5 (extreme fatigue). These activities ranged
in intensity from low (e.g. watching TV for 2 h) to high
(e.g. high-intensity activity for 30 min). Responses to each
item were summed to create a total physical fatigability
score ranging from 0 (no physical fatigue) to 50 (extreme
physical fatigue). Higher physical fatigability was classiﬁed
as PFS ≥ 15. Where ≤3 items were missing but a related
question on whether the activity had been done in the past
month was complete (n= 289 in analytic sample), values
for missing responses were imputed based on the
mean value of an individual’s valid responses with
adjustments made to take account of the varying intensity
levels of the different activities and differences in the levels
of fatigue reported by study members who had and had not
done each speciﬁed activity (see Supplementary text for
details).
Ascertainment of BMI and inﬂammatory markers
Height and weight measured by nurses using standard
protocols at ages 43 and 60–64 were used to calculate BMI
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(weight (kg)/height 2 (m2)). BMI was modelled as a con-
tinuous variable and also categorised into four
standard groups: underweight (<20.0 kg/m2); normal weight
(20.0–24.9 kg/m2); overweight (25.0–29.9 kg/m2); obese
(≥30.0 kg/m2). At age 60–64, measures of body
composition were also obtained for 1658 study members
who attended a clinical research facility, in the supine
position using a QDR 4500 Discovery DXA scanner
(Hologic Inc, Bedford, MA). Fat mass index was derived by
dividing whole-body fat mass (excluding the head) (kg) by
height2 (m2).
C-reactive protein (CRP) and interleukin-6 (IL-6) were
measured in overnight fasting blood samples taken by
nurses at age 60–64. After initial processing of the blood
samples at clinical research facility laboratories, aliquots
were frozen before being transferred to the MRC Human
Nutrition Research laboratory in Cambridge where analyses
of CRP were processed according to standardised protocols
using a particle-enhanced immunoturbidimetric assay.
Analyses of IL-6 were subsequently undertaken by the
British Heart Foundation Research Centre in Glasgow using
ELISA (enzyme-linked immunosorbent assay). Due to the
skewed nature of their distributions both CRP and IL-6
were log-transformed when modelled continuously. Both
variables were also categorised into four groups; cut-points
for CRP were based on CDC/AHA criteria [44] with the
addition of an upper category to distinguish acute inﬂam-
mation as follows: <1.00 mg/L; 1.00–3.00 mg/L;
3.01–10.00 mg/L; >10.00 mg/L. Cut-points for IL-6 were
those identiﬁed as equivalent to the CRP cut-points in a
previous study:[26] <1.50 pg/mL; 1.50–2.50 pg/mL;
2.51–8.49 pg/mL; ≥8.50 pg/mL.
Covariates
Factors which may confound the main associations of
interest were selected a priori. This included: sex; leisure
time physical activity and smoking status; symptoms of
anxiety and depression; diabetes, cardiovascular disease,
respiratory symptoms and medication use; educational level
and occupational class. With the exception of the indicators
of socioeconomic position, these were assessed at age
60–64.
Behavioural risk factors
Study members were asked to report whether or not they
had participated in any sports, vigorous leisure activities or
exercises in their spare time, not including getting to and
from work, in the last 4 weeks and, if so, on how many
occasions. This information was categorised as: inactive
(reported no participation); moderately active (participated
in relevant activities 1–4 times in the previous 4 weeks);
most active (participated in relevant activities ≥ 5 times in
the previous 4 weeks). Self-reported smoking status was
categorised as: current; ex; never smoker.
Health status
The General Health Questionnaire-28 was used to
distinguish those study members with symptoms of anxiety
and depression from those without using a threshold
of ≥5 for caseness [45]. Self-reports of diabetes and doctor
diagnosed angina and myocardial infarction from
assessments undertaken up to and including age 60–64 were
used to distinguish between study members with and
without reports of type II diabetes and cardiovascular
disease. Respiratory symptoms were assessed using the UK
Medical Research Council’s standardised questions [46]. A
group with the most severe symptoms were identiﬁed
who reported one or more of the following: a wheezy or
whistling chest most days or nights; usually bringing up
phlegm or coughing in the morning or during the
day or night in winter for at least 3 months each year; or
more than one chest illness in the last 3 years that kept them
off work or indoors for 1 week or more. A variable was
derived to indicate whether or not study members reported
taking medication that may affect their inﬂammatory status
or levels of fatigue. Medications included were: lipid low-
ering drugs, aspirin, oral steroids, hormone replacement
therapy, anti-depressants, hypnotics, anti-inﬂammatories,
disease modifying anti-rheumatic drugs, thyroid medica-
tion, weight reduction drugs and central nervous system
stimulants.
Socioeconomic position
Educational level attained by age 26 was categorised into
ﬁve groups: degree or higher; A levels, usually attained at
age 18, or their equivalents; O levels, usually attained at age
16, or their equivalents; CSE, clerical course or equivalent;
none. Occupational class at age 53 (or if not available,
the most recent measure in adulthood) was categorised
using the Registrar General’s Social Classiﬁcation into
three groups: high (I or II); middle (IIINM or IIIM); low
(IV or V).
We also investigated the possibility of reverse causality
by taking account of prior reports of fatigue using data
from the nurse home visit at age 43. Fatigue was
ascertained at this age using responses to the question
‘over the last year how often have there been days
when you tired out very easily?’ with six response options
collapsed into three categories: no (never); occasional
(occasionally or sometimes); frequent (quite often,
very often or always), consistent with previous NSHD
analyses [47].
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Statistical analyses
To address the primary aim, linear regression models were
used to test the associations of BMI, IL-6 and CRP at age
60–64 with the PFS score at age 68. Likelihood ratio tests of
interactions between sex and each explanatory factor were
undertaken and all subsequent models were sex-adjusted as
no evidence of sex differences was found. Tests of deviation
from linearity were undertaken for each explanatory mea-
sure by: adding a quadratic term to a sex-adjusted model
including a continuous linear term and; comparing models
with the categorised version of each measure treated as
categorical and linear. As there was evidence of deviations
from linearity for all three main associations (quadratic
terms for BMI and IL-6 p < 0.01; likelihood ratio tests, p <
0.01 for BMI and IL-6 and p= 0.04 for CRP) all sub-
sequent models were run using the categorised versions of
the explanatory factors. The associations of BMI, IL-6 and
CRP with the PFS score were then mutually adjusted before
potential confounding factors and fatigue at 43 were added
to subsequent models.
Table 1 Characteristics of the MRC National Survey of Health and
Development (sample restricted to those with complete data on BMI
and inﬂammatory markers at age 60–64 and perceived physical
fatigability at age 68 (maximum n= 1580))
Men Women
na % or Mean
(SD)
na % or Mean
(SD)
Physical Fatigability Scale
Score at age 68
760 13.2 (8.9) 820 16.0 (9.1)
BMI at age 60–64b
Underweight 10 1.3 25 3.1
Normal weight 193 25.4 271 33.1
Overweight 367 48.3 305 37.2
Obese 190 25.0 219 26.7
CRP (mg/l) at age 60–64
<1.00 197 25.9 181 22.1
1.00–3.00 339 44.6 371 45.2
3.01–10.00 185 24.3 224 27.3
>10.00 39 5.1 44 5.4
IL-6 (pg/mL) at age 60–64
<1.50 281 37.0 319 38.9
1.50–2.50 225 29.6 251 30.6
2.51–8.49 216 28.4 216 26.3
≥8.50 38 5.0 34 4.2
Covariates (at age 60–64 unless indicated otherwise)
Leisure time physical activity
Inactive 452 60.9 474 59.1
Moderately active 107 14.4 125 15.6
Most active 183 24.7 203 25.3
Smoking status
Current 67 9.5 77 9.9
Ex 435 61.5 427 55.0
Never 205 29.0 272 35.1
Symptoms of anxiety & depression
Yes 87 11.7 165 20.6
No 660 88.4 636 79.4
Type II diabetes
Yes 60 7.9 34 4.2
No 700 92.1 785 95.9
Cardiovascular disease
Yes 61 8.9 25 3.3
No 621 91.1 725 96.7
Respiratory symptoms
Yes 120 17.6 134 17.7
No 561 82.4 624 82.3
Medication usec
Yes 327 43.0d 360 43.9d
No 433 57.0 460 56.1
Educational level attained by age 26
None 194 27.1 197 25.1
Table 1 (continued)
Men Women
na % or Mean
(SD)
na % or Mean
(SD)
CSE, clerical course or
equivalent
35 4.9 73 9.3
O levels, or their
equivalents
111 15.5 225 28.7
A levels, or their
equivalents
236 32.9 237 30.2
Degree or higher 141 19.7 52 6.6
Occupational class at age 53
Low (IV or V) 64 8.5 113 13.8
Middle (IIINM or IIIM) 233 30.9 358 43.7
High (I or II) 458 60.7 348 42.5
Fatigue at age 43 443 61.0 284 36.1
No 443 61.0 284 36.1
Occasional 229 31.5 356 45.3
Frequent 54 7.4 146 18.6
aTotal ns vary due to missing data
bCut-points for BMI (kg/m2): underweight (<20.0); normal weight
(20.0–24.9); overweight (25.0–29.9); obese (≥30.0)
cPrescribed at least one of the following medications: lipid lowering
drugs; aspirin; oral steroids; hormone replacement therapy; anti-
depressants; hypnotics; anti-inﬂammatories; disease modifying anti-
rheumatic drugs; thyroid medication; weight reduction drugs; central
nervous system stimulants
d1 medication: men: 24.1%; women: 26.8%; 2 medications: men:
16.5%; women: 11.1%; ≥3 medications: men: 2.5%; women: 6.0%
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To conﬁrm that any association between BMI and PFS
was driven by adiposity, analyses were run to test the
association of DXA-derived fat mass index with the PFS
score in the sub-group of study members with this measure.
Analyses of BMI were then repeated using the measure
from age 43.
To maintain statistical power and minimise bias, missing
values of the covariates in the sample with complete data on
BMI and both inﬂammatory markers at age 60–64 and the
PFS score at 68 (n= 1580) were imputed (leisure time
physical activity (n= 36), smoking (n= 97), symptoms of
anxiety and depression (n= 32), diabetes (n= 1), cardio-
vascular disease (n= 148), respiratory symptoms (n= 141),
educational level (n= 79), occupational class (n= 6) and
fatigue at 43 (n= 68)) using multiple imputation chained
equations implemented in Stata version 14. All analyses
were run across 20 imputed data sets and estimates were
combined using Rubin’s rules.
Sensitivity analyses were performed to test the main sex-
adjusted associations in the: maximum available samples;
the sample with complete data; the sample excluding those
289 study members for whom items were imputed when
generating the total PFS score.
Results
Characteristics of the main analytical sample are presented
in Table 1. Women had higher mean PFS scores at age 68
than men (p < 0.01) and also had greater prevalence of
higher perceived physical fatigability (49.4% (women) vs
37.0% (men), p < 0.01).
In sex-adjusted models, BMI, CRP and IL-6 at age
60–64 were each associated with PFS scores at age 68
(Table 2, model 1). Study members who were underweight
and those who were obese both had higher mean PFS scores
than those who were normal weight; differences in mean
PFS score= 4.43 (95% CI:1.37, 7.50) and 4.12 (2.93, 5.30)
for the underweight and obese groups when compared with
the normal weight group, respectively. For CRP and IL-6,
there was evidence of increases in mean PFS scores when
comparing those study members in the two middle cate-
gories of either measure to those in the lowest category,
however, associations were weaker among those with CRP
and IL-6 levels >10.00 mg/L and ≥8.50 pg/mL, respectively
(Table 2, model 1).
When BMI, IL-6 and CRP were included in the same
model, associations of BMI and IL-6 with PFS scores were
only partially attenuated (Table 2, model 2). However, the
association between CRP and PFS scores was fully atte-
nuated; adjustment for IL-6 had a greater impact on these
estimates than adjustment for BMI although both factors
contributed to this attenuation (Supplementary table 1).
Further attenuation of the associations of BMI and IL-6
with PFS scores occurred after adjustment for potential
confounding factors (Table 2, model 3), with adjustment for
markers of physical health having the greatest impact
(Supplementary table 1). For BMI, these adjustments had a
greater impact on the effect sizes for the obese group than
for the underweight group. Adjustment for fatigue at 43 had
limited impact and associations of BMI and IL-6 with PFS
scores were still evident in the fully adjusted model
(Table 2, model 4); differences in mean PFS score= 3.41
(0.59, 6.24) and 1.65 (0.46, 2.84) for the underweight and
obese groups when compared with the normal weight group
and, 2.78 (1.65, 3.91) when comparing those with an IL-6
of 2.51–8.49 pg/mL with those with levels <1.50.
Among the sub-group of study members with DXA
measures of fat mass at age 60–64, there was evidence of a
linear association between higher fat mass index and higher
PFS scores (Table 3). Obesity at age 43 was found to be
associated with higher mean PFS scores at age 68; sex-
adjusted difference in mean PFS score= 4.91 (3.25, 6.58)
when comparing those who were obese at age 43 with those
who were normal weight (Table 3). There was borderline
evidence that this association was stronger among women
than men (differences in mean PFS scores when comparing
obese vs normal weight= 2.72 (0.13, 5.31) for men and
6.40 (4.23, 8.57) for women, p-value for sex interaction=
0.05). There was no evidence of an association
between underweight at this younger age and PFS. As for
BMI at age 60–64, associations of fat mass index at age
60–64 and BMI at age 43 with PFS were partially atte-
nuated after adjustments for inﬂammatory markers and
other covariates but both associations were still evident in
fully adjusted models.
Findings were very similar and conclusions remained the
same when the main models were rerun on: maximum
available samples; the sample with complete data and; the
sample excluding those study members with imputed PFS
items (Supplementary table 2).
Discussion
In a nationally representative study population, BMI and IL-
6 (but not CRP) at age 60–64 were independently asso-
ciated with perceived physical fatigability at age 68. Those
who were underweight or obese and those with higher
levels of IL-6 (up to 8.50 pg/mL) had higher mean levels of
perceived physical fatigability than those of normal weight
and with lower levels of IL-6, respectively. These associa-
tions were not fully explained by adjustment for a range of
potential confounding factors including leisure time physi-
cal activity, smoking, health status and socioeconomic
position. Higher fat mass index at age 60–64 and obesity
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earlier in adulthood also showed independent associations
with perceived physical fatigability at age 68.
Our ﬁnding of a non-linear association between BMI at
age 60–64 and perceived physical fatigability at age 68 is
consistent with ﬁndings from some other previous studies
[27, 30, 32, 33]. However, as these previous studies were
cross-sectional and/or limited to women only, our study of
both sexes using a validated measure of situational fatigue
which also examines inter-relationships with inﬂammation
provides important new insights.
In one of the only other prospective, population-based
studies of the association between inﬂammation and self-
reported fatigue, participants in the Whitehall II study with
higher levels of CRP and IL-6 at a mean age of 50 years had
greater odds of incident fatigue after 3 years of follow-up
than participants with low levels of both markers whereas
those participants with higher levels of only one of these
two markers did not [26]. When we ran additional analyses
to investigate the combined effects of each pair of expla-
natory factors using a similar method to this previous study
to facilitate comparison (Supplementary table 3), the results
showed that in our study population, higher levels of IL-6
were associated with higher perceived physical fatigability
even if CRP levels were lower.
There is a plausible explanation for our ﬁnding.
Experimental evidence suggests that inﬂammation may be
related to physical fatigue via the direct inﬂuence of cir-
culating cytokines on the central nervous system [48, 49]. It
is proposed that a number of symptoms including physical
fatigue may be a manifestation of changes in neuronal
function that occur as a direct result of this process [18, 19,
50]. If this is one of the explanations for our observed
associations, IL-6, a pro-inﬂammatory cytokine that can
cross the blood–brain barrier, would be expected to play a
Table 2 Associations of BMI,
CRP and IL-6 at age 60–64 with
Pittsburgh Physical Fatigability
Scale (PFS) scores at age 68 (n
= 1580)
Difference in mean PFS score at age 68 (95% CI)
Model:
Adjustments:
1
Sex
2
1+other main explanatory
factors
3
2+covariates
4
3+fatigue at 43
BMI
Underweight 4.43 (1.37, 7.50) 4.47 (1.45, 7.48) 3.71 (0.86, 6.56) 3.41 (0.59, 6.24)
Normal weight 0 0 0 0
Overweight 1.33 (0.27, 2.39) 0.93 (−0.13, 1.98) 0.39 (−0.62, 1.40) 0.49 (−0.50, 1.49)
Obese 4.12 (2.93, 5.30) 2.87 (1.63, 4.11) 1.64 (0.44, 2.84) 1.65 (0.46, 2.84)
CRP (mg/l)
<1.00 0 0 0 0
1.00–3.00 0.50 (–0.62,
1.62)
−0.24 (−1.36, 0.87) −0.09 (−1.14,
0.97)
−0.02 (−1.06,
1.02)
3.01–10.00 2.63 (1.38, 3.89) 0.48 (−0.84, 1.80) 0.64 (−0.62, 1.90) 0.56 (−0.68, 1.81)
>10.00 1.43 (−0.71,
3.57)
−1.28 (−3.53, 0.97) −1.83 (−3.96,
0.30)
−1.87 (−3.98,
0.23)
IL-6 (pg/mL)
<1.50 0 0 0 0
1.50–2.50 2.33 (1.27, 3.39) 1.92 (0.83, 3.01) 1.25 (0.22, 2.29) 1.27 (0.24, 2.29)
2.51–8.49 4.76 (3.66, 5.85) 4.04 (2.86, 5.23) 2.74 (1.60, 3.88) 2.78 (1.65, 3.91)
≥8.50 2.09 (−0.07,
4.25)
2.12 (−0.15, 4.39) 1.39 (−0.76, 3.54) 1.56 (−0.57, 3.69)
Model adjustments:
1: Sex (likelihood ratio tests of sex interaction: BMI p= 0.09, CRP p= 0.27, IL-6 p= 0.57)
2: Sex and other two main explanatory factors
3: Model 2 plus behavioural risk factors (leisure time physical activity and smoking status); health status
(symptoms of anxiety and depression, type II diabetes, cardiovascular disease, respiratory symptoms,
medication use) and; indicators of socioeconomic position (educational level attained, occupational class)
4: Model 3 plus fatigue at age 43
For brevity, results are not presented for each individual set of adjustments. Please see Supplementary table 1
for ﬁndings from models including separate adjustments for each group of covariates included in models 2
and 3
Analyses run across 20 imputed data sets and results combined using Rubin’s rules. Cut-points for BMI (kg/
m2): underweight (<20.0); normal weight (20.0–24.9); overweight (25.0–29.9); obese (≥30.0)
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more direct role than CRP, an acute phase reactant, which is
further downstream and does not cross this barrier.
That we observe a levelling off in associations among
those with inﬂammatory markers above the 95th percentile
suggests that chronic low-grade inﬂammation, that typiﬁes
ageing, rather than acute infection, which results in tem-
porarily elevated levels, is driving the observed associa-
tions. Higher BMI across life is associated with greater
cumulative exposure to chronic low-grade inﬂammation
[35–38], partly explained by the fact that adipose tissue
produces and secretes pro-inﬂammatory cytokines [35]. The
inﬂammatory processes described above are therefore one
plausible explanation for associations between higher BMI
and physical fatigability. However, our ﬁndings suggest that
the association between BMI and physical fatigability is
only partially explained by inﬂammation. Additional
explanations thus need to be considered, especially as
associations were also robust to adjustment for indicators of
physical and mental health and behavioural risk factors
including leisure time physical activity.
Perceived physical fatigability may reﬂect an imbalance
between energy availability and demand [51]. As the
energetic demands of any given weight-bearing physical
task will increase as BMI increases, especially when this is
explained by an increase in fat mass as in our study, indi-
viduals with higher BMI would be expected to report higher
levels of physical fatigue. In previous NSHD analyses,
higher BMI and greater length of exposure to obesity were
shown to be associated with lower muscle quality at age
60–64 [52]. When completing any speciﬁed physical task
those with higher BMI will thus also have lower capacity to
complete the task, especially if they have been obese for
longer, further increasing their risk of experiencing fatigue.
Our ﬁnding of an association between obesity earlier in
adulthood and higher physical fatigability provides support
for this explanation. There was also some evidence to
suggest this association may be stronger among women
than men, possibly due to women’s greater average fat mass
for a given BMI.
While associations of underweight with physical fatig-
ability were more robust to adjustment than those for obe-
sity, only a very small group of study members were
underweight in our analytic sample at age 60–64 (n= 35).
Thus the number of cases of high physical fatigability
attributable to underweight, if this association was causal,
would be much lower than for obesity. Authors of previous
studies that have found higher physical fatigability among
those who were underweight have suggested that this could
be explained by the fact that low BMI often indicates
underlying disease processes [27, 30]. This may explain
why associations were observed with underweight at age
60–64 but not 43; disease would be expected to become an
Table 3 Associations of BMI at
age 43 and fat mass index at age
60–64 with Pittsburgh Physical
Fatigability Scale (PFS) scores
at age 68
Difference in mean PFS score at age 68 (95% CI)
Model:
Adjustments:
1
Sex
2
1+other main explanatory
factors
3
2+covariates
4
3+fatigue at 43
BMI at age 43 (N= 1502)
Underweight 0.91 (−1.15,
2.97)
0.93 (−1.10, 2.96) 0.66 (−1.27, 2.59) 0.41 (−1.50, 2.31)
Normal weight 0 0 0 0
Overweight 0.23 (−0.78,
1.23)
−0.40 (−1.41, 0.60) −0.77 (−1.72,
0.19)
−0.69 (−1.64,
0.25)
Obese 4.91 (3.25, 6.58) 3.60 (1.92, 5.27) 2.38 (0.74, 4.02) 2.51 (0.89, 4.13)
Fat mass index at age 60–64 (N= 1189)
Per 1 kg/m2 0.77 (0.61, 0.94) 0.65 (0.47, 0.84) 0.46 (0.29, 0.64) 0.46 (0.28, 0.63)
Model adjustments:
1: Sex (likelihood ratio tests of sex interaction: BMI p= 0.05, fat mass index p= 0.93; quadratic terms: BMI
p= 0.001, fat mass index p= 0.32)
2: Sex, IL-6 and CRP
3: Model 2 plus behavioural risk factors (leisure time physical activity and smoking status); health status
(symptoms of anxiety and depression, type II diabetes, cardiovascular disease, respiratory symptoms,
medication use) and; indicators of socioeconomic position (educational level attained, occupational class)
4: Model 3 plus fatigue at age 43
Sample restricted to those with complete data on BMI and inﬂammatory markers at age 60–64 and physical
fatigability at age 68 with Ns lower due to missing data on BMI at 43 and fat mass index in the main analytic
sample
Analyses run across 20 imputed data sets and results combined using Rubin’s rules. Cut-points for BMI (kg/
m2): underweight (<20.0); normal weight (20.0–24.9); overweight (25.0–29.9); obese (≥30.0)
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increasingly important determinant of low BMI at older
ages as the burden of disease increases. However, our
association between underweight at age 60–64 and physical
fatigability was only moderately attenuated after adjustment
for health status, though the potential for residual
confounding by other diseases and underlying
conditions including those not yet clinically manifest is
acknowledged.
Our analyses have a number of key strengths including
the use of a relatively large general population-based
sample with data ascertained prospectively across life.
We were also able to take account of a wide range of
potential confounders, including symptoms of anxiety and
depression and anti-depressant use, the importance of which
has been highlighted in a number of recent studies [53–55].
Another strength is the use of a validated measure of per-
ceived physical fatigability [39] which overcomes some
important limitations of other self-report fatigue measures.
To be eligible for inclusion in our analyses, study
members had to have completed a postal questionnaire at
age 68. As high levels of participation have been main-
tained across life, the sample remains largely representative
of the population from which it was drawn [43]. However,
study members of lower SEP and poorer health status are
more likely to have been lost to follow-up. While multiple
imputation was used to maximise the sample size and
minimise the level of bias introduced due to missing data on
covariates we did exclude those study members who did not
have complete data on BMI and inﬂammation at age 60–64
to ensure the models of our three main explanatory factors
were all run on the same n. When we compared those
1580 study members included in analyses with those 515
who had a valid PFS score but did not have complete data
on BMI and inﬂammation there were no differences in
mean PFS scores (14.6 vs 15.2, p= 0.27), behavioural risk
factors, CVD, respiratory symptoms, medication use,
occupational class or fatigue at 43 but the group excluded
did have higher prevalence of obesity, anxiety and depres-
sion and diabetes and lower levels of education. While it is
possible that bias may have been introduced due to these
sample restrictions, when basic sex-adjusted analyses were
rerun on the maximum available samples, ﬁndings remained
the same (Supplementary table 2).
Another potential limitation of our analyses is the use of
only two inﬂammatory markers which had been measured
just once, at age 60–64. Alongside which, our selected
measure of physical fatigability was only ascertained at age
68. However, there are strengths of using IL-6 if only a
limited number of markers are available [56] and we were
able to assess the potential for reverse causality by adjusting
for an earlier measure of fatigue. While BMI has been
measured at multiple ages in the NSHD, we focused on age
60–64 so that we could investigate inter-relationships with
inﬂammation. In additional analyses, in which we examined
BMI at age 43, selected because the prevalence of obesity
ﬁrst exceeded 10% in the NSHD at this age [57],
associations extending back into earlier adulthood were
evident. This suggests the need to investigate the longer
term longitudinal inter-relationships of BMI and inﬂam-
mation with physical fatigability. This will be especially
important in cohorts born more recently who have experi-
enced higher prevalence of obesity, and therefore longer
term exposure to low-grade systemic inﬂammation, from
younger ages [57].
Our ﬁndings suggest that BMI and inﬂammation are both
suitable targets for intervention to reduce the burden of
physical fatigability in later life. In addition, our ﬁnding that
associations of BMI and IL-6 were additive suggest that
interventions that target both risk factors may be more
effective than those focusing on only one.
Acknowledgements We thank Robert Boudreau and Megan Marron at
the University of Pittsburgh for their valuable contributions to the
development and validation of the adjusted PFS. We are also grateful
to NSHD study members for their continuing support. Data used in
this publication are available to bona ﬁde researchers upon request to
the NSHD Data Sharing Committee via a standard application pro-
cedure. Further details can be found at http://www.nshd.mrc.ac.uk/data
doi: 10.5522/NSHD/Q101; doi: 10.5522/NSHD/Q102; doi: 10.5522/
NSHD/Q103
Author contributions Study concept and design: RC, MP, RH, DK.
Acquisition of data: RC, MP, RH, NWG, DK. Analysis of data: RC,
MP. Interpretation of data: all authors. Preparation of manuscript: all
authors.
Funding RC, MP, RH and DK are supported by the UK Medical
Research Council (Programme codes MC_UU_12019/4,
MC_UU_12019/1 and MC_UU_12019/2). The MRC National Survey
of Health and Development is funded by the UK Medical Research
Council. The funders of the study had no role in the study design, data
collection, data analysis, data interpretation, writing of the report or the
decision to submit the article for publication.
Compliance with ethical standards
Conﬂict of interest The authors declare that they have no conﬂict of
interest.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
R. Cooper et al.
References
1. Avlund K. Fatigue in older populations. Fatigue Biomed Health
Behav. 2013;1:43–63.
2. Alexander NB, Taffet GE, Horne FM, Eldadah BA, Ferrucci L,
Nayﬁeld S, et al. Bedside-to-Bench conference: research agenda
for idiopathic fatigue and aging. J Am Geriatr Soc.
2010;58:967–975.
3. Eldadah BA. Fatigue and fatigability in older adults. PM R.
2010;2:406–13.
4. Beutel ME, Weidner K, Schwarz R, Brahler E. Age-related
complaints in women and their determinants based on a repre-
sentative community study. Eur J Obstet Gynecol Reprod Biol.
2004;117:204–12.
5. Loge JH, Ekeberg O, Kaasa S. Fatigue in the general Norwegian
population: normative data and associations. J Psychosom Res.
1998;45:53–65.
6. Meng H, Hale L, Friedberg F. Prevalence and predictors of fatigue
in middle-aged and older adults: evidence from the health and
retirement study. J Am Geriatr Soc. 2010;58:2033–4.
7. Gill TM, Desai MM, Gahbauer EA, Holford TR, Williams CS.
Restricted activity among community-living older persons: inci-
dence, precipitants, and health care utilization. Ann Intern Med.
2001;135:313–21.
8. Avlund K, Pedersen AN, Schroll M. Functional decline from age
80 to 85: inﬂuence of preceding changes in tiredness in daily
activities. Psychosom Med. 2003;65:771–7.
9. Moreh E, Jacobs JM, Stessman J. Fatigue, function, and mortality
in older adults. J Gerontol A Biol Sci Med Sci. 2010;65:887–95.
10. Hardy SE, Studenski SA. Fatigue predicts mortality in older
adults. J Am Geriatr Soc. 2008;56:1910–4.
11. Simonsick EM, Glynn NW, Jerome GJ, Shardell M, Schrack JA,
Ferrucci L. Fatigued, but not frail: perceived fatigability as a
marker of impending decline in mobility-intact older adults. J Am
Geriatr Soc. 2016;64:1287–92.
12. Basu N, Yang X, Luben RN, Whibley D, Macfarlane GJ, Ware-
ham NJ, et al. Fatigue is associated with excess mortality in the
general population: results from the EPIC-Norfolk study. BMC
Med. 2016;14:122.
13. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C,
Gottdiener J, et al. Frailty in older adults: evidence for a pheno-
type. J Gerontol A Biol Sci Med Sci. 2001;56:M146–M156.
14. Fougere B, Boulanger E, Nourhashemi F, Guyonnet S, Cesari M.
Chronic inﬂammation: accelerator of biological aging. J Gerontol
A Biol Sci Med Sci. 2017;72:1218–25.
15. Franceschi C, Campisi J. Chronic inﬂammation (inﬂammaging)
and its potential contribution to age-associated diseases. J Ger-
ontol A Biol Sci Med Sci. 2014;69(Suppl 1):S4–S9.
16. Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F,
et al. Inﬂammaging and anti-inﬂammaging: a systemic perspective
on aging and longevity emerged from studies in humans. Mech
Ageing Dev. 2007;128:92–105.
17. Avlund K. Fatigue in older adults: an early indicator of the aging
process? Aging Clin Exp Res. 2010;22:100–15.
18. Capuron L, Miller AH. Immune system to brain signaling: neu-
ropsychopharmacological implications. Pharmacol Ther.
2011;130:226–38.
19. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW.
From inﬂammation to sickness and depression: when the
immune system subjugates the brain. Nat Rev Neurosci.
2008;9:46–56.
20. Bautmans I, Gorus E, Njemini R, Mets T. Handgrip performance
in relation to self-perceived fatigue, physical functioning and
circulating IL-6 in elderly persons without inﬂammation. BMC
Geriatr. 2007;7:5.
21. Lim W, Hong S, Nelesen R, Dimsdale JE. The association of
obesity, cytokine levels, and depressive symptoms with diverse
measures of fatigue in healthy subjects. Arch Intern Med.
2005;165:910–5.
22. Silva JP, Pereira DS, Coelho FM, Lustosa LP, Dias JM,
Pereira LS. Clinical, functional and inﬂammatory factors
associated with muscle fatigue and self-perceived fatigue in
elderly community-dwelling women. Rev Bras Fisioter.
2011;15:241–8.
23. Valentine RJ, McAuley E, Vieira VJ, Baynard T, Hu L, Evans
EM, et al. Sex differences in the relationship between obesity, C-
reactive protein, physical activity, depression, sleep quality and
fatigue in older adults. Brain Behav Immun. 2009;23:643–8.
24. Valentine RJ, Woods JA, McAuley E, Dantzer R, Evans EM. The
associations of adiposity, physical activity and inﬂammation
with fatigue in older adults. Brain Behav Immun.
2011;25:1482–90.
25. Cho HJ, Seeman TE, Bower JE, Kiefe CI, Irwin MR. Prospective
association between C-reactive protein and fatigue in the coronary
artery risk development in young adults study. Biol Psychiatry.
2009;66:871–8.
26. Cho HJ, Kivimaki M, Bower JE, Irwin MR. Association of C-
reactive protein and interleukin-6 with new-onset fatigue in the
Whitehall II prospective cohort study. Psychol Med.
2013;43:1773–83.
27. Bultmann U, Kant IJ, Kasl SV, Schroer KA, Swaen GM, van den
Brandt PA. Lifestyle factors as risk factors for fatigue and psy-
chological distress in the working population: prospective results
from the Maastricht Cohort Study. J Occup Environ Med.
2002;44:116–24.
28. Chen MK. The epidemiology of self-perceived fatigue among
adults. Prev Med. 1986;15:74–81.
29. Coakley EH, Kawachi I, Manson JE, Speizer FE, Willet WC,
Colditz GA. Lower levels of physical functioning are associated
with higher body weight among middle-aged and older women.
Int J Obes Relat Metab Disord. 1998;22:958–65.
30. Jing MJ, Wang JJ, Lin WQ, Lei YX, Wang PX. A community-
based cross-sectional study of fatigue in middle-aged and elderly
women. J Psychosom Res. 2015;79:288–94.
31. Lin WQ, Jing MJ, Tang J, Wang JJ, Zhang HS, Yuan LX, et al.
Factors associated with fatigue among men aged 45 and older: A
cross-sectional study. Int J Environ Res Public Health.
2015;12:10897–909.
32. Resnick HE, Carter EA, Aloia M, Phillips B. Cross-sectional
relationship of reported fatigue to obesity, diet, and physical
activity: results from the third national health and nutrition
examination survey. J Clin Sleep Med. 2006;2:163–9.
33. Theorell-Haglow J, Lindberg E, Janson C. What are the important
risk factors for daytime sleepiness and fatigue in women? Sleep.
2006;29:751–7.
34. Ward-Ritacco CL, Adrian AL, O’Connor PJ, Binkowski JA,
Rogers LQ, Johnson MA, et al. Feelings of energy are associated
with physical activity and sleep quality, but not adiposity, in
middle-aged postmenopausal women. Menopause.
2015;22:304–11.
35. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB.
Elevated C-reactive protein levels in overweight and obese adults.
JAMA. 1999;282:2131–5.
36. Murray ET, Hardy R, Hughes A, Wills A, Sattar N, Deanﬁeld J,
et al. Overweight across the life course and adipokines, inﬂam-
matory and endothelial markers at age 60-64 years: evidence from
the 1946 birth cohort. Int J Obes. 2015;39:1010–8.
37. Forsythe LK, Wallace JM, Livingstone MB. Obesity and
inﬂammation: the effects of weight loss. Nutr Res Rev.
2008;21:117–33.
Are BMI and inﬂammatory markers independently associated with physical fatigability in old age?
38. Tzoulaki I, Jarvelin MR, Hartikainen AL, Leinonen M, Pouta A,
Paldanius M, et al. Size at birth, weight gain over the life course,
and low-grade inﬂammation in young adulthood: northern Finland
1966 Birth Cohort study. Eur Heart J. 2008;29:1049–56.
39. Glynn NW, Santanasto AJ, Simonsick EM, Boudreau RM, Beach
SR, Schulz R, et al. The Pittsburgh Fatigability scale for older
adults: development and validation. J Am Geriatr Soc.
2015;63:130–5.
40. Cooper R, Huang L, Hardy R, Crainiceanu A, Harris T, Schrack
JA, et al. Obesity history and daily patterns of physical activity at
age 60-64 years: Findings from the MRC National Survey of
Health and Development. J Gerontol Med Sci. 2017;72:1424–30.
41. Wadsworth M, Kuh D, Richards M, Hardy R. Cohort proﬁle: The
1946 National Birth Cohort (MRC National Survey of Health and
Development). Int J Epidemiol. 2006;35:49–54.
42. Kuh D, Pierce M, Adams J, Deanﬁeld J, Ekelund U, Friberg P,
et al. Cohort proﬁle: updating the cohort proﬁle for the MRC
National Survey of Health and Development: a new clinic-based
data collection for ageing research. Int J Epidemiol. 2011;40:
e1–e9.
43. Kuh D, Wong A, Shah I, Moore A, Popham M, Curran P, et al.
The MRC National Survey of Health and Development reaches
age 70: maintaining participation at older ages in a birth cohort
study. Eur J Epidemiol. 2016;31:1135–47.
44. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon
RO III, Criqui M, et al. Markers of inﬂammation and cardiovas-
cular disease: application to clinical and public health practice: a
statement for healthcare professionals from the Centers for Dis-
ease Control and Prevention and the American Heart Association.
Circulation. 2003;107:499–511.
45. Goldberg DP, Hillier VF. A scaled version of the General Health
Questionnaire. Psychol Med. 1979;9:139–45.
46. Medical Research Council. Questionnaire on Respiratory Symp-
toms and Instructions for Interviewers. London: Medical Research
Council; 1976.
47. Manty M, Kuh D, Cooper R. Associations of midlife to late life
fatigue with physical performance and strength in early old age:
Results from a British prospective cohort study. Psychosom Med.
2015;77:823–32.
48. Banks WA. Blood-brain barrier transport of cytokines: a
mechanism for neuropathology. Curr Pharm Des.
2005;11:973–84.
49. Yarlagadda A, Alfson E, Clayton AH. The blood brain barrier and
the role of cytokines in neuropsychiatry. Psychiatry.
2009;6:18–22.
50. Dantzer R, Kelley KW. Twenty years of research on cytokine-
induced sickness behavior. Brain Behav Immun. 2007;21:
153–60.
51. Schrack JA, Simonsick EM, Ferrucci L. The energetic pathway to
mobility loss: an emerging new framework for longitudinal stu-
dies on aging. J Am Geriatr Soc. 2010;58:S329–S336.
52. Cooper R, Hardy R, Bann D, Aihie SA, Ward KA, Adams JE,
et al. Body mass index from age 15 years onwards and muscle
mass, strength, and quality in early old age: ﬁndings from the
MRC National Survey of Health and Development. J Gerontol A
Biol Sci Med Sci. 2014;69:1253–9.
53. Brown PJ, Badreddine D, Roose SP, Rutherford B, Ayonayon
HN, Yaffe K, et al. Muscle fatigability and depressive symptoms
in later life. Int J Geriatr Psychiatry. 2017;32:e166–72.
54. Jokela M, Virtanen M, Batty GD, Kivimaki M. Inﬂammation and
speciﬁc symptoms of depression. JAMA Psychiatry.
2016;73:87–88.
55. White J, Kivimaki M, Jokela M, Batty GD. Association of
inﬂammation with speciﬁc symptoms of depression in a general
population of older people: The English Longitudinal Study of
Ageing. Brain Behav Immun. 2017;61:27–30.
56. Metti AL, Aizenstein H, Yaffe K, Boudreau RM, Newman A,
Launer L, et al. Trajectories of peripheral interleukin-6, structure
of the hippocampus, and cognitive impairment over 14 years in
older adults. Neurobiol Aging. 2015;36:3038–44.
57. Johnson W, Li L, Kuh D, Hardy R. How has the age-related
process of overweight or obesity development changed over time?
Co-ordinated analyses of individual participant data from ﬁve
United Kingdom Birth Cohorts. PLoS Med. 2015;12:e1001828.
R. Cooper et al.
